- Home
- CLMT vs RARE Comparison
CLMT vs RARE Comparison
Compare CLMT & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLMT
- RARE
- Stock Information
- Founded
- CLMT 1916
- RARE 2010
- Country
- CLMT United States
- RARE United States
- Employees
- CLMT N/A
- RARE 1294
- Industry
- CLMT Oil & Gas Production
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- CLMT Energy
- RARE Health Care
- Exchange
- CLMT Nasdaq
- RARE Nasdaq
- Market Cap
- CLMT N/A
- RARE 3.3B
- IPO Year
- CLMT 2006
- RARE 2014
- Fundamental
- Price
- CLMT $13.98
- RARE $34.03
- Analyst Decision
- CLMT Strong Buy
- RARE Strong Buy
- Analyst Count
- CLMT 6
- RARE 17
- Target Price
- CLMT $20.17
- RARE $92.29
- AVG Volume (30 Days)
- CLMT 1.1M
- RARE 1.0M
- Earning Date
- CLMT 05-09-2025
- RARE 05-06-2025
- Dividend Yield
- CLMT N/A
- RARE N/A
- EPS Growth
- CLMT N/A
- RARE N/A
- EPS
- CLMT N/A
- RARE N/A
- Revenue
- CLMT $4,177,500,000.00
- RARE $590,689,000.00
- Revenue This Year
- CLMT N/A
- RARE $18.68
- Revenue Next Year
- CLMT $2.93
- RARE $28.74
- P/E Ratio
- CLMT N/A
- RARE N/A
- Revenue Growth
- CLMT 0.68
- RARE 33.46
- 52 Week Low
- CLMT $7.68
- RARE $29.59
- 52 Week High
- CLMT $25.29
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- CLMT 62.00
- RARE 42.01
- Support Level
- CLMT $13.41
- RARE $33.97
- Resistance Level
- CLMT $14.83
- RARE $36.22
- Average True Range (ATR)
- CLMT 0.65
- RARE 1.33
- MACD
- CLMT 0.06
- RARE -0.13
- Stochastic Oscillator
- CLMT 61.19
- RARE 13.51
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.